Strong Q2 for Cipla amid waning generic Nexium impact
This article was originally published in Scrip
Executive Summary
Cipla reported robust growth in the second quarter ended September buoyed by one-off revenues from the US, but the company sought to temper full year top-line expectations in view of the strong showing in the first half.